Xenetic Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

• Xenetic Biosciences Inc XBIO.OQ reported a quarterly adjusted loss of 59 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -78 cents. The lone analyst forecast for the quarter was for a loss of 72 cents per share.

• Revenue rose 16.1% to $593.26 thousand from a year ago; analysts expected $670.00 thousand.

• Xenetic Biosciences Inc's reported EPS for the quarter was a loss of 59 cents​.

• The company reported a quarterly loss of $903.14 thousand.

• Xenetic Biosciences Inc shares had risen by 17.2% this quarter and lost 23.3% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

This summary was machine generated from LSEG data May 14 at 06:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)